Opposite effects of recombinant interferon-alpha A and deoxycoformycin on
adenosine deaminase activity in the Daudi B lymphoblastoid cell line
CR Faltynek
Program Resources, Inc., Frederick Cancer Research Facility, MD 21701.
Interferon-alpha and the adenosine deaminase (ADA) inhibitor
deoxycoformycin (dCF) have each been shown to be efficacious in the
treatment of some lymphoid malignancies and to have potent
antiproliferative activities in vitro. This study examined whether dCF and
recombinant interferon-alpha A (rIFN-alpha A) were additive, synergistic,
or antagonistic in their effects on the cultured B lymphoblastoid cell line
Daudi. Treatment of Daudi cells for three to four days with doses of
rIFN-alpha A that were growth inhibitory was unexpectedly found to increase
the level of ADA activity per cell two- to threefold and therefore to
prevent the inhibition of ADA by limiting concentrations of dCF. However,
the opposite effects of dCF and rIFN- alpha A on ADA activity did not lead
to antagonistic effects on growth inhibition. The higher concentrations of
dCF (with deoxyadenosine) necessary for appreciable growth inhibition could
inhibit the increased ADA activity in rIFN-alpha A-treated cells, thus
resulting in additive antiproliferative effects.
Volume 71,
Issue 1,
pp. 59-64,
01/01/1988
Copyright © 1988 by The American Society of Hematology
